- Mereo BioPharma Group plc (NASDAQ: MREO) rose 31.2% to $2.90 in pre-market trading after the company, and Ultragenyx, reported a license and collaboration agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.
No comments:
Post a Comment